Press Releases
June 18, 2024
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Additional Formats
June 17, 2024
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
Additional Formats
May 22, 2024
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
Additional Formats
May 16, 2024
CytomX Therapeutics Announces New Employment Inducement Grants
Additional Formats
May 8, 2024
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
Additional Formats
May 8, 2024
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Additional Formats
May 7, 2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
Additional Formats
May 1, 2024
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
Additional Formats
April 8, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Additional Formats
April 3, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Additional Formats
Displaying 1 - 10 of 18